Revelation Biosciences Inc Total Liabilities
Revelation Biosciences Inc total liabilities. Based on the latest financial reports, Revelation Biosciences Inc (REVB) has total liabilities worth $2.43 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Revelation Biosciences Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Revelation Biosciences Inc (2016–2025)
Total liabilities of Revelation Biosciences Inc from 2016 to 2025. This chart illustrates how Revelation Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Revelation Biosciences Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.
Revelation Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Revelation Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fluicell AB
ST:FLUI
|
Sweden | Skr6.56 Million |
|
Euro Menkul Kiymet Yatirim Ortakligi AS
IS:EUYO
|
Turkey | TL5.13 Million |
|
Pragma Inkaso S.A.
WAR:PRI
|
Poland | zł12.10 Million |
|
Largo SAS
PA:ALLGO
|
France | €14.88 Million |
|
PREMIER1 Lithium Ltd
AU:PLC
|
Australia | AU$353.76K |
|
International Biotechnology Trust plc
LSE:IBT
|
UK | GBX34.63 Million |
|
OMG Group Ltd
AU:OMG
|
Australia | AU$3.08 Million |
|
SIXTY SIX CAPITAL INC.
F:5CR0
|
Germany | €3.04 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Revelation Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Revelation Biosciences Inc's balance sheet.
Liquidity & Leverage Metrics
Revelation Biosciences Inc Total Liabilities Ratios Explained
Revelation Biosciences Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Revelation Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Revelation Biosciences Inc (2016–2025)
The table below shows the annual total liabilities of Revelation Biosciences Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.72 Million | +42.24% |
| 2024-12-31 | $1.91 Million | -65.61% |
| 2023-12-31 | $5.56 Million | +25.03% |
| 2022-12-31 | $4.45 Million | +107.83% |
| 2021-12-31 | $2.14 Million | -66.25% |
| 2020-12-31 | $6.34 Million | +24016.88% |
| 2019-12-31 | $26.31K | -100.00% |
| 2018-12-31 | $2.19 Billion | +14.64% |
| 2017-12-31 | $1.91 Billion | +10.72% |
| 2016-12-31 | $1.73 Billion | -- |
About Revelation Biosciences Inc
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregul… Read more